With proof of concept for its NAV platform from two gene therapy products partners have brought to the market, two products slated for regulatory submission in the next two years, and a new manufacturing facility, Regenxbio Inc. is poised to take the next step to becoming a fully realized commercial biotech, CEO Kenneth Mills told Scrip in a recent interview.
The progress is all part of the Rockville, MD-based biotech’s “5x25” strategy to bring five gene therapy candidates either to market or into pivotal-stage clinical trials by 2025, as is the company’s Manufacturing Innovation Center, which opened this summer with capability to produce clinical trial or commercial product up to 2,000 liters
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?